Adaptimmune Therapeutics PLC (ADAP.OQ)
23 Feb 2018
BRIEF-Adaptimmune Therapeutics Says On Jan 5, Co Entered Into Agreement With Cell, Gene Therapy Catapult For Vector Production In UK
* ADAPTIMMUNE THERAPEUTICS SAYS ON JAN 5, CO ENTERED INTO AGREEMENT WITH CELL AND GENE THERAPY CATAPULT FOR VECTOR PRODUCTION IN UK - SEC FILING
* ADAPTIMMUNE ANNOUNCES POSITIVE SAFETY DATA FROM PILOT STUDIES WITH MAGE-A10 SPEAR T-CELLS AND FIRST PATIENT TO RECEIVE 1 BILLION TARGET CELL DOSE
* Adaptimmune reports third quarter 2017 financial results and business updates
* Matrix Capital Management Company Lp reports 12.9 percent passive stake in Adaptimmune Therapeutics Plc as of August 31, 2017 - SEC filing Source text: (http://bit.ly/2wSEc1U)
LONDON GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas its has prioritized for research and development.
LONDON, Sept 7 GlaxoSmithKline said it has licensed the rights to Adaptimmune's pioneering T-cell therapy programme to boost its pipeline in oncology, one of four areas its has prioritised for research and development.
* Adaptimmune Therapeutics Plc - GSK exercises option over SPEAR T-cell therapy program targeting NY-ESO